Discuss everything about this article and breakdown for easy understanding and learning.

Reading File

Running Command

Reading File

I now have a comprehensive grasp of the entire article. Let me compose the full breakdown.

ASRA PM 5th Edition Guidelines: Regional Anesthesia in the Anticoagulated Patient - Complete Breakdown

Citation: Kopp SL, Vandermeulen E, McBane RD, Perlas A, Leffert L, Horlocker T. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: ASRA PM Evidence-Based Guidelines (Fifth Edition). Reg Anesth Pain Med 2025. doi:10.1136/rapm-2024-105766

1. What This Article Is and Why It Matters

This is the 5th edition of the landmark ASRA Pain Medicine (ASRA PM) guidelines on how to safely perform regional anesthesia - especially spinal/epidural (neuraxial) blocks - in patients taking blood thinners. It was published in 2025 and updates the prior 2018 4th edition.

The core problem it solves: Blood thinners are given to millions of patients to prevent clots. However, needles near the spine can cause bleeding into the spinal canal - a "neuraxial hematoma" - which can cause permanent paralysis. These guidelines help clinicians balance that risk.

Key numbers to appreciate:

Over 6 million Americans are on chronic anticoagulation
~20% will need an invasive procedure each year
Neuraxial hematoma is extremely rare but catastrophic when it occurs
Because it is so rare, randomized controlled trials (RCTs) are impossible - so this guideline relies on observational data, pharmacology, and expert consensus

2. Who Wrote It and How

The panel was international and multidisciplinary:

Kopp & Horlocker (Mayo Clinic) - regional anesthesia experts
Vandermeulen (Belgium) - international perspective
McBane (Mayo Clinic) - thrombophilia/hematology expert
Perlas (Toronto) - regional anesthesia expert
Leffert (Yale) - obstetric anesthesia expert

The guidelines were developed by reviewing literature from MEDLINE, EMBASE, Cochrane, and PubMed published after 2018. Recommendations were compared against those of:

SOAP (obstetric anesthesia society)
ESAIC/ESRA (European equivalents)
ACCP (American College of Chest Physicians)

The 5th edition is notably condensed and reorganized compared to prior editions - clinicians are told to reference the 4th edition for deep pharmacology background.

3. Grading System (How to Read the Recommendations)

Understanding the grades is essential for interpreting every recommendation:

Grade	Meaning
I	High level of evidence (well-done observational series with large risk reduction)
II	Moderate evidence (observational/epidemiological)
III	Case reports or expert opinion only
A	General agreement - safe to proceed
B	Conflicting evidence or opinions
C	Possibly harmful or unhelpful

"We recommend" = strong (IA, IB, IC) | "We suggest" = weaker (IIA, IIB, IIC)

Practical rule of thumb: Most DOAC recommendations are grade IIC - meaning limited evidence, expert-opinion driven, cautious approach. Most LMWH recommendations are grade IC or IA - more evidence-backed.

4. High/Low Risk Procedure Classification

Not all regional blocks are equal. The guidelines divide procedures into two risk tiers based on whether bleeding would compress the spinal cord or be impossible to compress:

High-Risk ("Neuraxial and Deep Plexus/Peripheral") Procedures

Spinal (intrathecal) injections
Epidural block and catheter placement/removal
Lumbar plexus block (psoas compartment)
Paravertebral block
Deep cervical plexus block
Celiac plexus block
Stellate ganglion block

Lower-Risk ("Superficial Peripheral") Procedures

Interscalene, supraclavicular, infraclavicular brachial plexus
Femoral, sciatic, popliteal nerve blocks
Most ultrasound-guided peripheral nerve blocks

Key principle: The stop-times described apply primarily to high-risk procedures. For superficial peripheral blocks, the risk of catastrophic hemorrhage is much lower (though bleeding can still cause hematoma or nerve damage).

5. Drug-by-Drug Breakdown of Recommendations

A. Direct Oral Anticoagulants (DOACs)

DOACs are now among the most commonly prescribed anticoagulants globally. The 5th edition introduces several new DOAC recommendations not in the 4th edition.

Understanding DOAC "High Dose" vs "Low Dose"

Drug	Low Dose (prophylactic)	High Dose (therapeutic)
Apixaban	2.5 mg BID	5 mg BID or 10 mg BID (initial VTE Rx)
Rivaroxaban	10 mg OD	15-20 mg OD
Edoxaban	N/A	30-60 mg OD
Dabigatran	110 mg OD (prophylaxis)	110-150 mg BID

Apixaban Stop Times Before Neuraxial/Deep Block

Dose	CrCl ≥30 mL/min	CrCl <30 mL/min
High dose	72 hours	96 hours
Low dose	48 hours	72 hours

Acceptable residual level: plasma <30 ng/mL or anti-Xa ≤0.1 IU/mL (new recommendation)
Resume low dose: 6 hours after needle/catheter removal
Resume high dose: 24 hours after (non-high-bleeding-risk procedure) or 48-72 hours after (high-risk surgery)

Rivaroxaban Stop Times

Dose	CrCl ≥30 mL/min	CrCl <30 mL/min
High dose	72 hours	96 hours
Low dose	24 hours	30 hours

Acceptable residual level: <30 ng/mL plasma or aXa ≤0.1 IU/mL (new)
Resume: 6 hours after needle/catheter removal

Edoxaban Stop Times (limited evidence - based on pharmacokinetics + expert opinion)

Dose	CrCl ≥30 mL/min	CrCl <30 mL/min
High dose	72 hours	96 hours
Low dose	24 hours	48 hours

Dabigatran Stop Times (most renal-dependent of all DOACs)

Dose	CrCl ≥50 mL/min	CrCl 30-49 mL/min
High dose	72 hours	120 hours
Low dose	48 hours	72 hours

Monitor via diluted thrombin time (dTT) - not regular TT
Acceptable level: dabigatran plasma <30 ng/mL
Note: Dabigatran is the only DOAC with an antidote - idarucizumab - but it is NOT FDA-approved for reversal prior to neuraxial procedures (only for emergencies/life-threatening bleeding)

Why These DOAC Times Matter Clinically

The PAUSE study confirmed that after stopping apixaban for ~64 hours, 93.1% of patients had plasma levels <30 ng/mL. For rivaroxaban at 72 hours, 85.3% achieved this. For dabigatran (CrCl ≥50) at 63 hours, 98.9% of patients had negligible levels.

The new principle: If you must proceed earlier than the recommended stop time, measure residual drug levels - acceptable if plasma <30 ng/mL or aXa ≤0.1 IU/mL.

Catheter Indwelling with DOACs

DOACs should NOT be given while an epidural catheter is in place (FDA labeling explicitly warns of this risk for apixaban and edoxaban)
If a DOAC is accidentally given with a catheter in place, wait the same interval as pre-procedure stop times (or confirm non-detectable levels) before removing the catheter

B. Unfractionated Heparin (UFH)

Subcutaneous (SC) prophylactic UFH:

Low dose (≤5000 U SC TID): No contraindication to neuraxial techniques; remove catheters 4-6 hours after dose
Higher dose (7500-10,000 U BID or ≤20,000 U/day total): Wait 12 hours + confirm normal coagulation before neuraxial block
Very high dose (>10,000 U per dose or >20,000 U/day): Wait 24 hours + confirm normal coagulation

Intravenous (IV) therapeutic UFH (e.g., intraoperative systemic heparinization):

Maintain at least a 1-hour interval between neuraxial needle placement and IV heparin administration
Before catheter removal: stop heparin for 4-6 hours, check coagulation status (aPTT/ACT)
~50% of spinal hematomas associated with IV heparinization occur at catheter removal - this is a critical danger point

Heparinization during cardiac surgery (CPB):

Full heparinization for CPB is given after epidural placement - the risk-benefit ratio remains heavily debated
No definitive recommendations here; each case must be individualized with surgeon input

Key concern with traumatic neuraxial procedure ("bloody tap"):

A bloody tap was a contributing factor in ~50% of spinal hematomas
No data support automatic cancellation, but direct communication with the surgeon and individual risk-benefit analysis is required

C. Low Molecular Weight Heparin (LMWH)

LMWH (enoxaparin, dalteparin, nadroparin) is the most evidence-based section of these guidelines.

Pharmacology essentials:

Peak anti-Xa: 3-5 hours after SC injection
Half-life: ~5 hours (normal renal function), up to 16 hours in severe renal impairment
Not fully reversible by protamine (only anti-IIa activity fully reversed; anti-Xa is not)
Acceptable anti-Xa level before neuraxial procedure: ≤0.1 IU/mL (new recommendation to measure this in high-risk patients)

Preoperative LMWH (prior to neuraxial block):

Dose	Stop Before Neuraxial
Low dose (prophylactic)	12 hours
High dose (therapeutic)	24 hours
High dose + renal impairment/elderly	Consider checking anti-Xa level

Postoperative LMWH (with neuraxial catheter in place):

Regimen	Rules
Twice-daily low dose	Catheters removed BEFORE starting; first dose next morning and ≥12 h after placement; restart ≥4 h after removal
Once-daily low dose	Catheter may remain; remove 12 h after last LMWH dose; next dose ≥4 h after removal
Therapeutic (high) dose	Remove catheter ≥4 h before first dose; first dose ≥24 h after placement

Important absolute rule (Grade IA): Do NOT combine LMWH with other hemostasis-altering agents (antiplatelet drugs, UFH, dextran) when a neuraxial catheter is in place.

D. Antiplatelet Agents

NSAIDs and Aspirin

NSAIDs/aspirin alone do NOT represent a contraindication to neuraxial techniques
No evidence that aspirin alone causes spinal hematoma
The risk rises significantly when combined with other anticoagulants

P2Y12 Inhibitors (Clopidogrel, Prasugrel, Ticagrelor)

Drug	Stop Before Neuraxial Block
Clopidogrel	5-7 days
Prasugrel	7-10 days
Ticagrelor	5-7 days

These drugs irreversibly (or slowly reversibly) inhibit platelet ADP receptors. New platelet production is needed for hemostasis to recover.

Cangrelor (IV P2Y12 inhibitor)

Very short-acting (platelet recovery in 60-90 minutes)
Used as bridging therapy when oral P2Y12 inhibitors are held before surgery
Minimum 3-hour interval before neuraxial block after stopping cangrelor
Important drug interaction: clopidogrel and prasugrel cannot work while cangrelor is infusing (receptor occupied); ticagrelor can be given during/after cangrelor

GP IIb/IIIa Inhibitors (Abciximab, Eptifibatide, Tirofiban)

Very high bleeding risk
These patients are generally poor candidates for neuraxial blocks
Recovery times: 8 hours (eptifibatide, tirofiban), 24-48 hours (abciximab)

Cilostazol

Weak, reversible platelet inhibition (PDE-IIIA inhibitor)
Half-life 11 hours (longer with renal impairment)
Discontinue 2 days before neuraxial or deep plexus/peripheral block

E. Parenteral Direct Thrombin Inhibitors (Argatroban, Bivalirudin, Desirudin)

Monitor with aPTT; no pharmacological antidote
No case reports of spinal hematoma with these agents, but spontaneous intracranial bleeding has been reported
These patients are typically on therapeutic anticoagulation (HIT treatment) - making them poor candidates
Recommendation: Suggest against neuraxial techniques in these patients (Grade IIC)

F. Fondaparinux (Parenteral Anti-Xa Agent)

Synthetic pentasaccharide; selective anti-Xa activity; no anti-IIa
FDA issued a black box warning similar to LMWH for neuraxial anesthesia
No case reports of spinal hematoma yet (very limited neuraxial exposure)
Long half-life (~21 hours); no antidote (andexanet alfa may be considered off-label)
Stop 72 hours before neuraxial block (based on pharmacokinetics)
Catheter removal: wait 6 hours after last dose; next dose 8 hours after removal

G. Fibrinolytic/Thrombolytic Agents (tPA, Streptokinase)

Lyse already-formed clots, including clots that may have formed at the site of neuraxial needle puncture
Significant risk of spinal hematoma if given after recent neuraxial procedure
Recommendation: Avoid neuraxial techniques within 10 days of thrombolytic therapy
If thrombolytics are given unexpectedly when an epidural catheter is in place:
- Do NOT remove catheter immediately
- Measure fibrinogen level (last clotting factor to recover - low fibrinogen indicates ongoing lytic effect)
- Neurological monitoring every 2 hours for at least 48 hours after last dose
- Minimize sensory/motor block in epidural infusion to detect new neurological changes

H. Warfarin (Vitamin K Antagonist)

Pharmacology reminder:

Inhibits synthesis of factors II, VII, IX, X (vitamin K-dependent)
Factor VII has a short half-life (~6 hours) - so early PT/INR rise reflects mostly factor VII reduction
Full reversal requires normalization of ALL factors (especially factors II and X with longer half-lives)
INR <1.5 associated with factor VII activity ~40% - adequate hemostasis

Pre-procedure management:

Stop warfarin 5 days before planned procedure; confirm INR normalized (Grade IB - strong recommendation)
If first dose was given >24 hours before planned needle: check INR before proceeding (Grade IIC)

During epidural catheter maintenance:

Check INR daily in patients receiving low-dose warfarin during epidural infusion (Grade IIC)
Remove catheter when INR <1.5 (Grade IIC)
If INR >1.5 but <3: maintain or remove with caution (Grade IIC)
If INR >3: hold or reduce warfarin dose (Grade IA - strong)

Post-removal monitoring:

Continue neurological assessment for at least 48 hours after catheter removal

Effect of herbal medicines on warfarin (Table in article):

Garlic, ginkgo, ginseng, and several other herbs can increase bleeding risk or alter INR
Current guideline: not necessary to routinely stop herbal medicines pre-procedure, but clinicians should be aware

6. Reversal Agents (New Section in 5th Edition)

For Factor Xa inhibitors (apixaban, rivaroxaban, edoxaban):

Andexanet alfa (Andexxa): FDA-approved reversal agent
- Low-dose regimen: 400 mg IV bolus + 480 mg IV over 120 min
- High-dose regimen: 800 mg IV bolus + 960 mg IV over 120 min
- Short half-life - must give infusion after bolus or drug rebounds from extravascular compartment
- Not specifically studied for neuraxial hematoma reversal

For dabigatran:

Idarucizumab (Praxbind): humanized monoclonal antibody fragment
- FDA-approved for emergency/urgent surgery or life-threatening bleeding with dabigatran
- Reverses dabigatran within 30 minutes, reducing plasma levels below 20 ng/mL
- NOT FDA-approved for reversal prior to neuraxial procedures
- French Working Group recommends it for urgent lumbar puncture in select cases (infectious CNS disease)
- Two case reports show successful use for emergency lumbar puncture
- Caution: thromboembolic risk after reversal; rare severe adverse effects with hereditary fructose intolerance

7. Special Populations

A. Obstetric Patients (Parturients)

This is a major section with important nuances, summarized in Box 1 of the article:

Why neuraxial anesthesia is preferred in obstetrics (even in anticoagulated patients when possible):

Avoids risks of general anesthesia (aspiration, difficult airway, awareness)
Avoids hypertensive response to intubation (critical in pre-eclampsia)
Less intraoperative blood loss, fewer wound infections
Superior postoperative analgesia
Immediate skin-to-skin bonding benefits
Fetal: better Apgar scores, avoids in-utero exposure to induction agents

General principle: Apply the same anticoagulation stop-time recommendations to parturients (Grade IIC).

Exception for high-risk parturients: In urgent situations (maternal or fetal indications) where general anesthesia poses greater risk than neuraxial anesthesia, exceptions/modifications of the standard stop times may be appropriate (Grade IIC). This is a clinically important nuance - it recognizes that in obstetrics, the risks of general anesthesia can outweigh the usual anticoagulation precautions.

Specific note on VTE prophylaxis in pregnancy:

Pregnant patients on LMWH prophylaxis: same LMWH stop-times apply (12 hours for prophylactic, 24 hours for therapeutic)
Given the benefits of neuraxial analgesia for labor and delivery, timing of LMWH doses relative to expected delivery should be planned in advance

B. Patients with Thrombophilia

Thrombophilia risk stratification is presented in the guidelines' Table (adapted from Douketis et al.):

Risk Level	Conditions
High (>10%/yr ATE or >10%/mo VTE)	Mechanical mitral valve; mechanical AVR + risk factors; AF with prior stroke/TIA; severe thrombophilia; antiphospholipid antibodies; active cancer with high VTE risk
Moderate (4-10%/yr ATE or 4-10%/mo VTE)	Mitral valve without major risk factors; CHA₂DS₂-VASc 5-6; VTE within 3-12 months; non-severe thrombophilia
Low (<4%/yr ATE or <2%/mo VTE)	Bileaflet AVR without risk factors; CHA₂DS₂-VASc 1-4; VTE >12 months ago

This stratification helps guide the risk-benefit decision of bridging therapy vs. stopping anticoagulation.

8. Plexus and Peripheral Nerve Blocks in the Anticoagulated Patient

This section is less data-rich because neuraxial hematoma is more studied. Key points:

Neuraxial hematoma remains the biggest concern because bleeding occurs in a fixed, non-compressible space
Risk of hemorrhagic complications after peripheral blocks is less defined
Fear of bleeding should not deter providers from performing peripheral blocks that would benefit the patient
Deep, non-compressible sites (lumbar plexus/psoas, paravertebral, celiac plexus) warrant the same precautions as neuraxial blocks
Superficial/compressible sites may tolerate shorter stop-times or have lower overall risk
Ultrasound guidance reduces but does not eliminate bleeding risk

9. Neuraxial Hematoma: Recognition and Emergency Management

The guidelines emphasize what to do when things go wrong:

Warning signs:

New or progressive back pain
New bladder/bowel dysfunction
Unexpectedly prolonged motor/sensory block after epidural

Action protocol:

Suspect hematoma immediately if neurological deficit develops or motor block does not resolve as expected
Urgent MRI - this is the imaging modality of choice
Emergent surgical decompression (laminectomy) if hematoma confirmed
Time to decompression is critical - outcomes are best when surgery occurs within 8 hours of symptom onset
Protocols for rapid MRI and neurosurgical consultation must be in place preemptively

Key epidemiological finding: In Vandermeulen's classic series, 87% of patients with spinal hematoma had an identifiable hemostatic abnormality or difficult needle placement - but 13% had NO identifiable risk factor. This is why vigilance cannot be abandoned even in seemingly low-risk cases.

10. Key New Recommendations in the 5th Edition (Summary of Changes from 4th Edition 2018)

Topic	Change
DOACs - dose stratification	New: separate recommendations for "high dose" vs "low dose" for each DOAC
Apixaban high dose	NEW: 72 h (CrCl ≥30) or 96 h (CrCl <30) before neuraxial
Apixaban low dose	NEW: 48 h (CrCl ≥30) or 72 h (CrCl <30) before neuraxial
Rivaroxaban high dose	NEW: 72 h (CrCl ≥30) or 96 h (CrCl <30) before neuraxial
Rivaroxaban low dose	NEW: 24 h (CrCl ≥30) or 30 h (CrCl <30) before neuraxial
Dabigatran high dose	NEW: 72 h (CrCl ≥50) or 120 h (CrCl 30-49) before neuraxial
Dabigatran low dose	NEW: 48 h (CrCl ≥50) or 72 h (CrCl <30) before neuraxial
Residual plasma level monitoring	NEW: acceptable threshold defined as <30 ng/mL (plasma) or ≤0.1 IU/mL (anti-Xa) for DOACs and LMWH
LMWH + renal impairment	NEW: suggest measuring anti-Xa in elderly/renal impairment
Reversal agents section	NEW expanded section on andexanet alfa and idarucizumab
Idarucizumab	NEW: described for off-label urgent lumbar puncture scenarios
Obstetric benefits table	NEW: Box 1 with comprehensive advantages of neuraxial vs GA in obstetrics
High/low risk procedure stratification	Reorganized and clarified

11. Take-Home Principles for Clinical Practice

Always stratify the procedure risk - deep/neuraxial vs. superficial peripheral before deciding on stop times.
Know your DOACs and their renal dependence - dabigatran is most affected by renal function; apixaban is least.
High dose always requires longer stop time than low dose - for every DOAC, high-dose therapeutic anticoagulation needs ~24-48 hours more than low-dose prophylaxis.
Catheter removal is as risky as insertion - half of all spinal hematomas associated with heparin occurred at catheter removal, not at insertion.
Never give LMWH with a neuraxial catheter in place alongside other hemostasis-altering drugs (Grade IA).
If in doubt, measure - new emphasis on lab confirmation (anti-Xa level, dTT for dabigatran, diluted TT) when timing is suboptimal.
In obstetrics, the risk of general anesthesia is real - the benefits of neuraxial anesthesia may justify proceeding even in imperfect anticoagulation situations with urgent maternal/fetal indications.
Neuraxial hematoma can happen without any risk factors in 13% of cases - maintain vigilance and neurological monitoring protocols regardless.
Warfarin requires complete normalization before neuraxial procedures - the INR reflects only factor VII early on; all factors must normalize.
Aspirin alone is not a contraindication - but any combination with anticoagulants dramatically increases risk.

This article is the most comprehensive and current practice reference for regional anesthesia in anticoagulated patients, and the 5th edition's most important contribution is the introduction of dose-stratified DOAC recommendations and the inclusion of measurable plasma level thresholds as an alternative to fixed time intervals - making management more individualized and precise.

Both 1 & 2

Asking for Preferences

This is a shared conversation. Sign in to Orris to start your own chat.